- The program focuses on antibiotic resistance in urinary tract infections (UTI-DR), with applications open until November 20; final awardees…
WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today…
Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2nd generation antisense oligonucleotide (ASO), in…
With a rise in COVID cases and seasonal flu, Cipla Health's trusted portfolio empowers everyday health decisions for Indian families…
June 17, 2025 04:00 ET | Source: Llusern Scientific CARDIFF, United Kingdom, June 17, 2025 (GLOBE NEWSWIRE) -- Llusern Scientific,…